Board Member
Dyne Therapeutics, Inc. (DYN)Equibles does not estimate personal net worth.
Get an email with a short summary when Dyne Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get DYN alertsJohn Cox is recorded as CEO and Board Member at Dyne Therapeutics, Inc. (DYN) since March 25, 2024. Dyne Therapeutics, Inc. reported in an 8-K filed March 25, 2024 that John Cox was appointed Class I director, effective March 25, 2024. Dyne Therapeutics, Inc. reported in an 8-K filed March 25, 2024 that John Cox was appointed President and Chief Executive Officer, effective March 25, 2024. John Cox has spoken on 2 investor events across 1 company, most recently for Dyne Therapeutics, Inc. on September 15, 2026. Dyne Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Dyne Therapeutics, Inc. includes John G. Cox (CEO and Board Member), Josh Brumm (CEO), Erick Lucera (CFO and Chief Accounting Officer) and 4 others.
“In addition, effective as of the Effective Date, Mr. Cox was elected as a Class I director to serve on the Board until the Company's 2024 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal.”
“On March 25, 2024, Dyne Therapeutics, Inc. (the "Company") announced that its Board of Directors (the "Board") had appointed John Cox as President and Chief Executive Officer of the Company succeeding Joshua Brumm, effective as of March 25, 2024 (the "Effective Date").”
“I think dying was really built on the notion that the delivery of genetic medicines, oligonucleotides, and neuromuscular diseases needed to be done in a way that would broadly and fully distribute the oligonucleotides to tissue and across the blood-brain barrier, and to do so in a way that would be considered a safe…”
“Well, I'll just mention a little bit about where we are at Dime right now. So it's an incredibly exciting time for us. This company, over the last couple of years, has been preparing for the moment right in front of us, which is to launch a very important medicine in DMD.”
2024-03-25–present
2024-03-25–present
Biotechnology · Healthcare
CEO, Board Member
2024-03-25–present
